DR info

臨床試験数 : 13 / 薬物数 : 19 - (DrugBank : 8) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 103

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Adipose derived stromal cells intravenously injected
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 1/Phase 2   NCT04711200   -
Clobetasol ointment
   University of California, Davis
      2016   Phase 1/Phase 2   NCT02319616   United States;
Cyclosporine 5 mg/kg bid days 0-14
   Vanderbilt University Medical Center
      2022   Phase 3   NCT02987257   United States;
Etanercept
   Abe Riichirou
      2021   Phase 2   JPRN-jRCTs031210325   Japan;
Etanercept 50 mg sc day 0 and day 3
   Vanderbilt University Medical Center
      2022   Phase 3   NCT02987257   United States;
Harmonized supportive care
   Vanderbilt University Medical Center
      2022   Phase 3   NCT02987257   United States;
Infliximab
   Massachusetts Eye and Ear Infirmary
      2010   Phase 1/Phase 2   NCT01256489   United States;
Intravenous immunoglobulin
   Nihon Pharmaceutical Co., Ltd
      2012   Phase 3   NCT01696500   Japan;
Isotretinoin
   Massachusetts General Hospital
      2016   -   NCT02795143   United States;
Methylprednisolone
   Morita Eishin
      2017   Phase 2   JPRN-jRCTs061180044   Germany;Japan;Taiwan;
NaCl
   University of Liege
      2016   Phase 4   NCT02739295   Belgium;
Palifermin
   Brett King
      2010   Phase 1/Phase 2   NCT02037347   United States;
Prednisolone
   Morita Eishin
      2017   Phase 2   JPRN-jRCTs061180044   Germany;Japan;Taiwan;
Recombinant granulocyte - colony stimulating factor
   University of Liege
      2016   Phase 4   NCT02739295   Belgium;
Remicaide (infliximab)
   Loyola University
      2006   Phase 2   NCT00372723   United States;
Site specific standard of care comparison
   Massachusetts General Hospital
      2021   -   NCT03585946   -
Topical infliximab
   James Chodosh, MD, MPH
      2014   Phase 1/Phase 2   NCT02126020   Canada;United States;